1. Market Research
  2. > Pathology
About 300 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030 ##.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • Germany

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030

  • $ 4750
  • May 2020
  • 200 pages

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drug Chapters Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and late stag

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • North America
  • United States

Bavencio

  • $ 10000
  • October 2018
  • 82 pages

Bavencio CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Bavencio : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Bavencio : Non-small cell lung cancer (NSCLC) ## Bavencio : Gastric cancer ## Bavencio : Head and neck cancer ## Bavencio : Ovarian cancer ## Bavencio : Bladde

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • North America
  • United States

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Lung Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy

The 2021-2026 World Outlook for Non-Small Cell Lung Cancer (NSCLC) Drugs

  • $ 995
  • November 2019
  • 301 pages

Given this caveat, in this report we define the sales of non-small cell lung cancer (NSCLC) drugs as including all commonly understood products falling within this broad category, such as chemotherapies, epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • Demand

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • November 2016
  • 608 pages

ANAPLASTIC LYMPHOMA KINASE INHIBITION IN NON-SMALL-CELL LUNG CANCER.

  • Epidemiology
  • Hospital
  • Lung Cancer
  • Lymphoma
  • Therapy

Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market

  • $ 4200
  • May 2017
  • 120 pages

(% market share) CHAPTER ##: PIPELINE DISRUPTORS: LYMPHOMA MARKET OPPORTUNITY Non-Hodgkin' s Lymphoma Table ##-##: Classification of Non-Hodgkin' s Lymphomas Hodgkin' s Lymphoma Figure ##-##: Global Incidence and Mortality of Lymphoma by Country, 2012* THE HEAVY HITT

  • Lung Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy

Opdivo 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 25 pages

Opdivo 2018 U. S.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States

Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

  • $ 6995
  • September 2019
  • 55 pages

An alternative HSP## inhibitor, NVP- AUY##, showed antitumor effects in SCLC when used in combination with ABT-##, a B-cell lymphoma ## (BCL-##) inhibitor.

  • Immunotherapy
  • Lung Cancer
  • Lymphoma
  • Therapy
  • United States

Entrectinib

  • $ 10000
  • August 2018
  • 15 pages

lymphoma kinase (ALK) proteins.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Lorlatinib

  • $ 10000
  • August 2018
  • 16 pages

lymphoma kinase (ALK) and ROS## tyrosine kinase inhibitor (TKI) with potential antineoplastic activity.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Alunbrig

  • $ 10000
  • August 2018
  • 16 pages

lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy

Zykadia

  • $ 10000
  • August 2018
  • 19 pages

lymphoma kinase (ALK).

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Xalkori

  • $ 10000
  • August 2018
  • 19 pages

lymphoma kinase (ALK) tyrosine kinases, which are implicated in the progression of several cancers, including non-small cell lung cancer (NSCLC).

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Ensartinib

  • $ 10000
  • August 2018
  • 16 pages

lymphoma kinase (ALK) inhibitor developed by Xcovery.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Alecensa

  • $ 10000
  • August 2018
  • 22 pages

lymphoma kinase (ALK) inhibitor developed by Roche and Chugai.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • European Union

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030

  • $ 4750
  • May 2020
  • 200 pages

Programmed death-ligand ## (PD-L##) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030 ##.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States
View report >

Therapy Market in China

  • March 2018
  • 39 pages

According to research article " Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of ##, ## cases", DLBCL accounts for c. ##% of total lymphoma cases, while FL represents c. ##% of all lymphoma cases.

  • Lung Cancer
  • Lymphoma
  • Therapy
  • China
  • Sino Biopharmaceutical Limited

Therapy Market in the US November 2019

Global Therapy Market January 2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on